SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Coutts, S.
Right arrow Articles by Berner, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coutts, S.
Right arrow Articles by Berner, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Pharmacological intervention in antibody mediated disease

SM Coutts

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA 92121, USA

ML Plunkett

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA 92121, USA

GM Iverson

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA 92121, USA

PA Barstad

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA 92121, USA

CM Berner

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA 92121, USA

The use of single signal anergy to inactive pathological B cells in an antigen-specific manner is discussed. Cross-linking surface immunoglobulin, with a construct which contains oligo valent B cell epitopes on a non-immunogenic molecular framework can be used to inac tivate the target B cells if the construct lacks T cells epitopes. An example of such a B cell toleragen is LJP 394, which inactivates anti-dsDNA-specific B cells in vivo in murine immu nized and spontaneous disease models. The drug enhances survival and lowers renal pathol ogy in BXSB mice. Appropriate definition of epitopes of pathological (auto) antibodies thus offers an opportunity for pharmacological intervention.

Key Words: LJP 394 • tolerance • B cells • anti-dsDNA • Lupus • systemic lupus erythematosus (SLE) • antibody • antibody-mediated disease

Lupus, Vol. 5, No. 2, 158-159 (1996)
DOI: 10.1177/096120339600500214
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
D J Wallace and J A Tumlin
LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus
Lupus, May 1, 2004; 13(5): 323 - 327.
[Abstract] [PDF]

Home page
 LupusHome page
J T Merrill
LJP 1082: a toleragen for Hughes syndrome
Lupus, May 1, 2004; 13(5): 335 - 338.
[Abstract] [PDF]

Home page
 LupusHome page
V Strand, C Aranow, M H Cardiel, D Alarcon-Segovia, R Furie, Y Sherrer, J Tumlin, D J Wallace, LJP 394 Investigator Consortium, and B Crawford
Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo
Lupus, September 1, 2003; 12(9): 677 - 686.
[Abstract] [PDF]

Home page
 LupusHome page
P A Mcneeley, G M Iverson, R A Furie, J M Cash, M E Cronin, R S Katz, M H Weisman, C Aranow, and M D Linnik
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients
Lupus, August 1, 2001; 10(8): 526 - 532.
[Abstract] [PDF]


Advertisement